https://www.oncomine.com/

Since the introduction of integrated histological and [[molecular diagnostics]] by the [[2016]] World Health Organization (WHO) Classification of Tumors of the Nervous System, an increasing number of molecular markers have been found to have prognostic significance in infiltrating gliomas, many of which have now become incorporated as diagnostic criteria in the [[2021]] WHO Classification. This has increased the applicability of targeted-next generation [[sequencing]] in the diagnostic work-up of [[neuropathology]] [[specimen]]s and in addition, raises the question of whether [[targeted sequencing]] can, in practice, reliably replace older, more traditional diagnostic methods such as [[immunohistochemistry]] and [[Fluorescence in situ hybridization]]. 
Slocum et al. demonstrated that the [[Oncomine]] Cancer Gene Mutation Panel v2 assay targeted-next generation sequencing panel for solid tumors is not only superior to IHC in detecting mutation in [[IDH1]]/2 and [[TP53]] but can also predict [[1p/19q co-deletion]] with high sensitivity and specificity relative to [[Fluorescence in situ hybridization]] by looking at average copy number of genes sequenced on 1p, 1q, 19p, and 19q. Along with detecting the same molecular data obtained from older methods, targeted-next generation sequencing with an RNA sequencing component provides additional information regarding the presence of RNA based alterations that have diagnostic significance and possible therapeutic implications. They advocate for expanded use of targeted-next generation sequencing over more traditional methods for the detection of important molecular alterations as a part of the standard diagnostic work up for [[Central nervous system tumor]]s
((Slocum CC, Park HJ, Baek I, Catalano J, Wells MT, Liechty B, Mathew S, Song W, Solomon JP, Pisapia DJ. Towards a single-assay approach: a combined DNA/RNA sequencing panel eliminates diagnostic redundancy and detects clinically-relevant fusions in neuropathology. Acta Neuropathol Commun. 2022 Nov 17;10(1):167. doi: 10.1186/s40478-022-01466-w. PMID: 36397144; PMCID: PMC9670552.))